

Massimo Zucchetti

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4994012/massimo-zucchetti-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

151
papers

4,405
citations

36
h-index

59
g-index

153
ext. papers

4,928
ext. citations

5.2
avg, IF

4.68
L-index

#	Paper	IF	Citations
151	Pharmacokinetic Characterization of the DDAH1 Inhibitors ZST316 and ZST152 in Mice Using a HPLC-MS/MS Method.. <i>Molecules</i> , 2022 , 27,	4.8	1
150	Quantitative measurement of pioglitazone in neoplastic and normal tissues by AP-MALDI mass spectrometry imaging. <i>Talanta</i> , 2022 , 237, 122918	6.2	1
149	Pharmacological and clinical monitoring in children with acute lymphoblastic leukemia treated with a biogeneric PEG-l-asparaginase product.. <i>Pediatric Blood and Cancer</i> , 2022 , e29753	3	1
148	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. <i>Matrix Biology</i> , 2021 , 103-104, 22-36	11.4	0
147	Betulinic acid and its spray dried microparticle formulation: In vitro PDT effect against ovarian carcinoma cell line and in vivo plasma and tumor disposition. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2021 , 224, 112328	6.7	0
146	Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile. <i>Targeted Oncology</i> , 2021 , 16, 59-68	5	4
145	Preformed Biodegradable Zwitterionic Nanoparticles as Tunable Excipients for the Formulation of Therapeutics Directly at the Point of Care. <i>Industrial & Engineering Chemistry Research</i> , 2021 , 60, 10699-10709	3.9	2
144	First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 873-877	8.9	4
143	THE SPACE DIMENSION AT THE MICRO LEVEL: MASS SPECTROMETRY IMAGING OF DRUGS IN TISSUES. <i>Mass Spectrometry Reviews</i> , 2021 , 40, 201-214	11	6
142	Population Pharmacokinetics of PEGylated Asparaginase in Children with Acute Lymphoblastic Leukemia: Treatment Phase Dependency and Predictivity in Case of Missing Data. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021 , 46, 289-300	2.7	1
141	Venetoclax penetrates in cerebrospinal fluid of an acute myeloid leukemia patient with leptomenigeal involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 1	3.5	0
140	PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 286	12.8	4
139	Quantitative determination of niraparib and olaparib tumor distribution by mass spectrometry imaging. <i>International Journal of Biological Sciences</i> , 2020 , 16, 1363-1375	11.2	7
138	High-dose vitamin C enhances cancer immunotherapy. <i>Science Translational Medicine</i> , 2020 , 12,	17.5	65
137	CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. <i>Cells</i> , 2020 , 9,	7.9	12
136	Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. <i>Haematologica</i> , 2020 , Online ahead of print,	6.6	11
135	HPLC-MS/MS measurement of lidocaine in rat skin and plasma. Application to study the release from medicated plaster. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020 , 1138, 121942	3.2	1

134	Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group. <i>Cancer</i> , 2020 , 126, 4726-4734	6.4	8
133	Therapeutic Drug Monitoring of Asparaginase: Intra-individual Variability and Predictivity in Children With Acute Lymphoblastic Leukemia Treated With PEG-Asparaginase in the AIEOP-BFM Acute Lymphoblastic Leukemia 2009 Study. <i>Therapeutic Drug Monitoring</i> , 2020 , 42, 435-444	3.2	6
132	Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death. <i>Blood Advances</i> , 2020 , 4, 4312-4326	7.8	7
131	A novel oral micellar fenretinide formulation with enhanced bioavailability and antitumour activity against multiple tumours from cancer stem cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 373	12.8	16
130	Asparagine levels in the cerebrospinal fluid of children with acute lymphoblastic leukemia treated with pegylated-asparaginase in the induction phase of the AIEOP-BFM ALL 2009 study. <i>Haematologica</i> , 2019 , 104, 1812-1821	6.6	19
129	Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2019 , 142, 455-462	4.8	11
128	Venetoclax penetrates in cerebrospinal fluid and may be effective in chronic lymphocytic leukemia with central nervous system involvement. <i>Haematologica</i> , 2019 , 104, e222-e223	6.6	24
127	Pharmacokinetics of cisplatin during open and minimally-invasive secondary cytoreductive surgery plus HIPEC in women with platinum-sensitive recurrent ovarian cancer: a prospective study. <i>Journal of Gynecologic Oncology</i> , 2019 , 30, e59	4	20
126	Monitoring the Fate of Orally Administered PLGA Nanoformulation for Local Delivery of Therapeutic Drugs. <i>Pharmaceutics</i> , 2019 , 11,	6.4	4
125	Readily prepared biodegradable nanoparticles to formulate poorly water soluble drugs improving their pharmacological properties: The example of trabectedin. <i>Journal of Controlled Release</i> , 2018 , 276, 140-149	11.7	9
124	Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells. <i>Neoplasia</i> , 2018 , 20, 467-477	6.4	7
123	Prompt detection of L-asparaginase inactivation is crucial to optimize treatment efficacy also in aggressive lymphomas. <i>Hematological Oncology</i> , 2018 , 36, 498-499	1.3	
122	Self-Assembling PCL-Based Nanoparticles as PTX Solubility Enhancer Excipients. <i>Macromolecular Bioscience</i> , 2018 , 18, e1800164	5.5	8
121	Tumor progression and metastatic dissemination in ovarian cancer after dose-dense or conventional paclitaxel and cisplatin plus bevacizumab. <i>International Journal of Cancer</i> , 2018 , 143, 2187-2199	7.5	7
120	Therapeutic Drug Monitoring of Asparaginase Activity-Method Comparison of MAAT and AHA Test Used in the International AIEOP-BFM ALL 2009 Trial. <i>Therapeutic Drug Monitoring</i> , 2018 , 40, 93-102	3.2	11
119	Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group. <i>Lancet Oncology</i> , 2018 , 19, 1360-1371	21.7	38
118	High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation. <i>Pharmaceutical Research</i> , 2017 , 34, 1180-1186	4.5	13
117	Pharmacodynamic effects in the cerebrospinal fluid of rats after intravenous administration of different asparaginase formulations. <i>Cancer Chemotherapy and Pharmacology</i> , 2017 , 79, 1267-1271	3.5	3

116	Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy. <i>Neurobiology of Disease</i> , 2017 , 99, 12-23	7.5	114
115	In Vitro and In Vivo Activity of Lucitanib in FGFR1/2 Amplified or Mutated Cancer Models. <i>Neoplasia</i> , 2017 , 19, 35-42	6.4	15
114	Application of 3D Mass Spectrometry Imaging to TKIs. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 748-751	6.1	11
113	Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein. <i>Biochemical Pharmacology</i> , 2017 , 144, 52-62	6	8
112	Bioreducible Hydrophobin-Stabilized Supraparticles for Selective Intracellular Release. <i>ACS Nano</i> , 2017 , 11, 9413-9423	16.7	31
111	A Nanostructured Matrices Assessment to Study Drug Distribution in Solid Tumor Tissues by Mass Spectrometry Imaging. <i>Nanomaterials</i> , 2017 , 7,	5.4	11
110	Susceptibility of different mouse strains to oxaliplatin peripheral neurotoxicity: Phenotypic and genotypic insights. <i>PLoS ONE</i> , 2017 , 12, e0186250	3.7	39
109	3D Mass Spectrometry Imaging Reveals a Very Heterogeneous Drug Distribution in Tumors. <i>Scientific Reports</i> , 2016 , 6, 37027	4.9	45
108	PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers. <i>Molecular Pharmaceutics</i> , 2016 , 13, 40-6	5.6	29
107	Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 477-84	3.5	8
106	Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 125-35	6.1	47
105	A phase 1b trial with the combination of trabectedin and olaparib in relapsed patients (pts) with advanced and unresectable bone and soft tissue sarcomas (BSTS): An Italian Sarcoma Group (ISG) study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11018-11018	2.2	4
104	Self-assembling amphiphilic PEGylated block copolymers obtained through RAFT polymerization for drug-delivery applications. <i>Journal of Applied Polymer Science</i> , 2016 , 133, n/a-n/a	2.9	12
103	Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging. <i>Scientific Reports</i> , 2016 , 6, 39284	4.9	47
102	HPLC-MS/MS method to measure trabectedin in tumors: preliminary PK study in a mesothelioma xenograft model. <i>Bioanalysis</i> , 2015 , 7, 1831-42	2.1	7
101	Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. <i>British Journal of Cancer</i> , 2015 , 112, 306-12	8.7	61
100	Intratumor heterogeneity and its impact on drug distribution and sensitivity. <i>Clinical Pharmacology and Therapeutics</i> , 2014 , 96, 224-38	6.1	51
99	New class of squalene-based releasable nanoassemblies of paclitaxel, podophyllotoxin, camptothecin and epothilone A. <i>European Journal of Medicinal Chemistry</i> , 2014 , 85, 179-90	6.8	27

98	Phase Ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. <i>Oncologist</i> , 2014 , 19, 344-5	5.7	6
97	Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. <i>Annals of Oncology</i> , 2014 , 25, 2244-2251	10.3	133
96	HPLC-MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E-3810 in tumor tissues from xenograft mice and human biopsies. <i>Journal of Mass Spectrometry</i> , 2014 , 49, 19-26	2.2	3
95	Immediate cooling does not prevent the ex vivo hydrolysis of L-asparagine by asparaginase. <i>Therapeutic Drug Monitoring</i> , 2014 , 36, 549-52	3.2	14
94	Quantification of trabectedin in human plasma: validation of a high-performance liquid chromatography-mass spectrometry method and its application in a clinical pharmacokinetic study. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 95, 107-12	3.5	12
93	Trabectedin and indole-3-carbinol combination in heavily pretreated metastatic breast cancer: Results of a pilot clinical study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e12015-e12015	2.2	
92	The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2013 , 12, 131-40	6.1	36
91	A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma. <i>European Journal of Cancer</i> , 2013 , 49, 290-6	7.5	66
90	Imaging mass spectrometry: challenges in visualization of drug distribution in solid tumors. <i>Current Opinion in Pharmacology</i> , 2013 , 13, 807-12	5.1	24
89	Role of macrophage targeting in the antitumor activity of trabectedin. <i>Cancer Cell</i> , 2013 , 23, 249-62	24.3	568
88	Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 879-87	3.5	26
87	Tumor delivery of chemotherapy combined with inhibitors of angiogenesis and vascular targeting agents. <i>Frontiers in Oncology</i> , 2013 , 3, 259	5.3	61
86	Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging. <i>PLoS ONE</i> , 2013 , 8, e72532	3.7	48
85	Chemical characterization of Iraqi propolis samples and assessing their antioxidant potentials. <i>Food and Chemical Toxicology</i> , 2011 , 49, 2415-21	4.7	59
84	In vivo comparative study of the cytotoxicity of a liposomal formulation of cisplatin (lipoplatin) <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 1001-8	3.5	21
83	Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study. <i>Journal of Mass Spectrometry</i> , 2011 , 46, 1039-45	2.2	4
82	Metabolic approach to the enhancement of antitumor effect of chemotherapy: a key role of acetyl-L-carnitine. <i>Clinical Cancer Research</i> , 2010 , 16, 3944-53	12.9	22
81	Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels. <i>European Journal of Cancer</i> , 2010 , 46, 505-16	7.5	11

80	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 335-46	3.5	37
79	Antitumor activity and pharmacokinetics of oral gimatecan on pediatric cancer xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 66, 635-41	3.5	7
78	Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2010 , 65, 1197-202	3.5	10
77	Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel proteasome inhibitor CEP-18770 in human plasma and its application in a clinical pharmacokinetic study. <i>Journal of Mass Spectrometry</i> , 2009 , 44, 1003-1011	2.2	8
76	Development and validation of a liquid chromatography-tandem mass spectrometry method for the determination of ST1926, a novel oral antitumor agent, adamantyl retinoid derivative, in plasma of patients in a Phase I study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 2118-21	3.2	20
75	Development and validation of a LC-MS/MS method for the determination of the novel oral 1,14 substituted taxane derivatives, IDN 5738 and IDN 5839, in mouse plasma and its application to the pharmacokinetic study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2009 , 877, 1147-53	3.2	8
74	Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 563-6	3.5	10
73	Determination of total and lactone form of a new camptothecin derivative gimatecan (ST1481) and its metabolite ST1698 in human plasma by high-performance liquid chromatography with fluorimetric detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2009 , 50, 507-14	3.5	5
72	Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. <i>European Journal of Cancer</i> , 2009 , 45, 1153-1161	7.5	47
71	Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. <i>European Journal of Cancer</i> , 2009 , 45, 2116-22	7.5	30
70	Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. <i>Journal of Mass Spectrometry</i> , 2008 , 43, 216-23	2.2	21
69	Imatinib concentrations in human milk. <i>Blood</i> , 2007 , 109, 1790-1790	2.2	23
68	Sequence dependent antitumour efficacy of the vascular disrupting agent ZD6126 in combination with paclitaxel. <i>British Journal of Cancer</i> , 2007 , 97, 888-94	8.7	45
67	Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2007 , 18, 561-8	10.3	17
66	Imatinib concentrations in human milk. <i>Blood</i> , 2007 , 109, 1790	2.2	22
65	Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2006 , 58, 319-25	3.5	17
64	Biological properties of IDN5174, a new synthetic camptothecin with the open lactone ring. <i>Cancer Research</i> , 2006 , 66, 10976-82	10.1	15
63	Pharmacokinetics and metabolism in mice of IDN 5390 (13-(N-Boc-3-i-butylisoserinoyl)-C-7,8-seco-10-deacetylbaaccatin III), a new oral c-seco-taxane derivative with antiangiogenic property effective on paclitaxel-resistant tumors. <i>Drug Metabolism and Disposition</i> , 2006 , 34, 2028-35	4	16

62	A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. <i>Haematologica</i> , 2006 , 91, 24-31	6.6	58
61	The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: a comparative study with SN38 and topotecan. <i>Biochemical Pharmacology</i> , 2005 , 70, 1125-36	6	24
60	Pharmacokinetic study of intravesical gemcitabine in carcinoma in situ of the bladder refractory to bacillus Calmette-Guérin therapy. <i>Urologia Internationalis</i> , 2005 , 75, 309-13	1.9	16
59	Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 53, 89-90	3.5	11
58	Determination of aplidin, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2004 , 34, 619-30	3.5	16
57	Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2004 , 18, 1017-23	2.2	21
56	Dietary agent indole-3-carbinol protects female rats against the hepatotoxicity of the antitumor drug ET-743 (trabectedin) without compromising efficacy in a rat mammary carcinoma. <i>International Journal of Cancer</i> , 2004 , 111, 961-7	7.5	31
55	Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2003 , 52, 131-8	3.5	66
54	High-performance liquid chromatographic assay for the determination of Aloe Emodin in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003 , 796, 113-9	3.2	19
53	IDN 5390: an oral taxane candidate for protracted treatment schedules. <i>British Journal of Cancer</i> , 2003 , 88, 965-72	8.7	16
52	Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. <i>Clinical Cancer Research</i> , 2003 , 9, 625-32	12.9	136
51	Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug yondelis (ET-743) in the rat. <i>Cancer Research</i> , 2003 , 63, 5902-8	10.1	48
50	High-performance liquid chromatographic assay for the determination of the novel C-Seco-taxane derivative (IDN 5390) in mouse plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2002 , 780, 93-8	3.2	5
49	Binding of imatinib by alpha(1)-acid glycoprotein. <i>Blood</i> , 2002 , 100, 367-8; author reply 368-9	2.2	34
48	Differences between in vivo and in vitro sensitivity to imatinib of Bcr/Abl+ cells obtained from leukemic patients. <i>Blood Cells, Molecules, and Diseases</i> , 2002 , 28, 361-72	2.1	26
47	High-performance liquid chromatography/tandem mass spectrometry for the quantitative analysis of a novel taxane derivative (BAY59-8862) in biological samples and characterisation of its metabolic profile in rat bile samples. <i>Rapid Communications in Mass Spectrometry</i> , 2001 , 15, 1807-16	2.2	9
46	A novel taxane active against an orthotopically growing human glioma xenograft. <i>Cancer</i> , 2001 , 92, 3085-92	6.2	15
45	Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: a multicentric phase I-II study. <i>Annals of Oncology</i> , 2000 , 11, 985-91	10.3	45

44	Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin. <i>British Journal of Cancer</i> , 2000 , 82, 524-8	8.7	6
43	The pharmacokinetics of liposomal encapsulated daunorubicin are not modified by HAART in patients with HIV-associated Kaposi's sarcoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 45, 495-501	10.3	27
42	L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure. <i>Annals of Oncology</i> , 2000 , 11, 189-93	10.3	76
41	Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. <i>Annals of Oncology</i> , 2000 , 11, 977-83	10.3	55
40	Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1641-50	9.7	241
39	Oral efficacy and bioavailability of a novel taxane. <i>Clinical Cancer Research</i> , 2000 , 6, 2070-4	12.9	27
38	Analysis of aplidine (dehydrodidemnin B), a new marine-derived depsipeptide, in rat biological fluids by liquid chromatography-tandem mass spectrometry. <i>Biomedical Applications</i> , 1999 , 731, 335-43		18
37	High-performance liquid chromatographic assay for the determination of the novel taxane derivative IDN5109 in mouse plasma. <i>Biomedical Applications</i> , 1999 , 736, 135-41		5
36	Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 178-9	3.5	13
35	Distribution of daunorubicin and daunorubicinol in human glioma tumors after administration of liposomal daunorubicin. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 173-6	3.5	50
34	Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243). <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 44, 403-10	3.5	14
33	Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin. <i>Annals of Oncology</i> , 1999 , 10, 391-5	10.3	27
32	High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol) in human plasma. <i>Rapid Communications in Mass Spectrometry</i> , 1998 , 12, 251-5	2.2	53
31	cis-Diamminedichloroplatinum(II) given in low-dose continuous infusion with concurrent radiotherapy to patients affected by inoperable lung carcinoma: a pharmacokinetic approach. <i>Journal of Cancer Research and Clinical Oncology</i> , 1998 , 124, 37-43	4.9	11
30	Pharmacokinetics of anticancer agents in patients with impaired liver function. <i>European Journal of Cancer</i> , 1998 , 34, 33-46	7.5	93
29	Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days. <i>Annals of Oncology</i> , 1998 , 9, 1315-22	10.3	41
28	Short course infusional idarubicin plus intermittent cytarabine and etoposide for refractory hematologic malignancies: clinical and preliminary pharmacological results. <i>Haematologica</i> , 1998 , 83, 27-33	6.6	4
27	Structural characterization of mono- and dihydroxylated metabolites of paclitaxel in rat bile using liquid chromatography/ion spray tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 1997 , 11, 1025-32	2.2	13

26	L-Asparagine depletion in plasma and cerebro-spinal fluid of children with acute lymphoblastic leukemia during subsequent exposures to Erwinia L-asparaginase. <i>Annals of Oncology</i> , 1996 , 7, 725-30	10.3	31
25	Paclitaxel induces significant changes in epidoxorubicin distribution in mice. <i>Annals of Oncology</i> , 1996 , 7, 801-5	10.3	15
24	Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 38, 541-7	3.5	24
23	Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days. <i>Investigational New Drugs</i> , 1996 , 14, 379-86	4.3	9
22	High-performance liquid chromatographic assay for the determination of the novel etoposide derivative dimethylaminoetoposide (NK611) and its metabolites in urine of cancer patients. <i>Biomedical Applications</i> , 1995 , 664, 409-14		5
21	Phase I clinical and pharmacokinetic study of oral etoposide phosphate. <i>Journal of Clinical Oncology</i> , 1995 , 13, 200-9	2.2	22
20	Changes in doxorubicin distribution and toxicity in mice pretreated with the cyclosporin analogue SDZ PSC 833. <i>Cancer Chemotherapy and Pharmacology</i> , 1995 , 36, 335-40	3.5	36
19	Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. <i>Medical and Pediatric Oncology</i> , 1995 , 24, 154-9		51
18	High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma. <i>Biomedical Applications</i> , 1994 , 654, 97-102		9
17	Determination of L-asparagine in biological samples in the presence of L-asparaginase. <i>Biomedical Applications</i> , 1994 , 657, 47-52		26
16	Cyclosporin A markedly changes the distribution of doxorubicin in mice and rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1994 , 269, 22-7	4.7	38
15	Low-dose oral etoposide in epithelial cancer of the ovary. <i>Annals of Oncology</i> , 1993 , 4, 517-9	10.3	20
14	Mass spectrometric identification and analysis of some aphidicolin metabolites in cancer patients. <i>Biological Mass Spectrometry</i> , 1993 , 22, 351-7		
13	A limited sampling model for the pharmacokinetics of etoposide given orally. <i>Cancer Chemotherapy and Pharmacology</i> , 1993 , 32, 482-6	3.5	27
12	Activity of aphidicolin glycinate alone or in combination with cisplatin in a murine ovarian tumor resistant to cisplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 30, 459-64	3.5	11
11	Do anticancer agents reach the tumor target in the human brain?. <i>Cancer Chemotherapy and Pharmacology</i> , 1992 , 30, 251-60	3.5	112
10	Concentrations of VP16 and VM26 in human brain tumors. <i>Annals of Oncology</i> , 1991 , 2, 63-6	10.3	18
9	Phase I and clinical pharmacological evaluation of aphidicolin glycinate. <i>Journal of the National Cancer Institute</i> , 1991 , 83, 1160-4	9.7	54

8	Pharmacokinetics of intrapleural versus intravenous etoposide (VP 16) and teniposide (VM 26) in patients with malignant pleural effusion. <i>Oncology</i> , 1990 , 47, 55-61	3.6	7
7	Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 25, 445-8	3.5	26
6	A gas chromatographic mass spectrometric assay for the determination of aphidicolin in plasma of cancer patients. <i>Journal of Pharmaceutical Sciences</i> , 1989 , 78, 399-401	3.9	2
5	Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation. <i>Biochemical Pharmacology</i> , 1989 , 38, 2069-75	6	10
4	Lack of effect of cisplatin on i.v. L-PAM plasma pharmacokinetics in ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1988 , 22, 87-9	3.5	6
3	Phase I study of the antifolate N10-propargyl-5,8-dideazafolic acid, CB 3717. <i>European Journal of Cancer & Clinical Oncology</i> , 1988 , 24, 769-75		19
2	Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. <i>Cancer Research</i> , 1986 , 46, 2566-71	10.1	75
1	Pharmacokinetics of teniposide in patients with ovarian cancer. <i>Cancer Treatment Reports</i> , 1985 , 69, 73-7		12